retatrutide is it a glp1 review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity | European Journal of Clinical Pharmacology Retatrutide Half Life: A Doctor

This journey is more than just the weight loss results

A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice

7 BrunhamL

What Emerging Research Says GLP-1 Medications May Do to Your Bones - The Studies Your Doctor May Not Have Read Yet Quick Answer: Emerging research from 2024-2025 suggests GLP-1 receptor agonist medications may be associated with bone density changes in specific populations, primarily driven by rapid weight loss rather than a confirmed direct drug effect on bone cells

Still, the researchers called for further research to collect more conclusive data

For a broader overview of dosing strategy, our semaglutide dosage guide offers a helpful companion read